Published in J Natl Cancer Inst on May 03, 2000
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma | NCT00226915
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc) | NCT01506856
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin (2011) 2.57
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol (2009) 2.33
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 1.85
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47
Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2005) 1.40
Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer. Int J Clin Oncol (2006) 1.39
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer (2002) 1.24
Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer (2003) 1.23
HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn (2009) 1.16
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer (2003) 1.11
Ascites and a raised serum Ca 125--confusing combination. J R Soc Med (2001) 1.08
Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol (2001) 1.06
Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol (2013) 1.01
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer (2004) 0.99
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer (2001) 0.99
Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol (2013) 0.98
Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer (2003) 0.98
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer (2003) 0.98
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer (2005) 0.98
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol (2013) 0.97
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol (2010) 0.96
Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer (2003) 0.96
Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer (2014) 0.96
Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep (2014) 0.95
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer (2009) 0.95
Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model. Drug Des Devel Ther (2009) 0.94
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol (2012) 0.94
Ovarian cancer standard of care: are there real alternatives? Chin J Cancer (2015) 0.94
TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 0.94
Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol (2010) 0.94
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol (2011) 0.92
Considering usual medical care in clinical trial design. PLoS Med (2009) 0.91
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem (2010) 0.91
Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol (2010) 0.91
Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol (2010) 0.91
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer (2011) 0.90
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer (2003) 0.90
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol (2015) 0.90
Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Invest New Drugs (2009) 0.89
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. Br J Cancer (2010) 0.88
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer (2009) 0.88
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer (2006) 0.87
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res (2013) 0.87
Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer. Cancer Res Treat (2012) 0.87
Characterization of a clinical polymer-drug conjugate using multiscale modeling. Biopolymers (2010) 0.87
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse. BMC Cancer (2012) 0.86
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol (2012) 0.86
Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp (2011) 0.85
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
Ovarian cancer treatment: The end of empiricism? Cancer (2015) 0.85
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res (2014) 0.85
Preclinical profile of cabazitaxel. Drug Des Devel Ther (2014) 0.85
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem (2009) 0.84
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer (2005) 0.84
A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol (2013) 0.84
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Chemotherapy: Current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol (2010) 0.84
Bevacizumab and ovarian cancer. Ther Adv Med Oncol (2013) 0.83
First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One (2014) 0.83
Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep (2015) 0.83
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int (2015) 0.82
Whole abdominal radiotherapy in ovarian cancer. Rep Pract Oncol Radiother (2010) 0.82
Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82
The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol (2011) 0.82
Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer (2005) 0.82
Prognostic factors in early-stage ovarian cancer. Ecancermedicalscience (2013) 0.82
Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy. Int J Clin Exp Pathol (2013) 0.81
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol (2007) 0.81
Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. BMC Cancer (2010) 0.81
Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. Onco Targets Ther (2013) 0.81
Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma. Cochrane Database Syst Rev (2011) 0.81
Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy. J Gynecol Oncol (2013) 0.80
Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol (2013) 0.80
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer (2007) 0.80
Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells. Br J Cancer (2008) 0.80
Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol (2010) 0.80
Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. Oncol Lett (2016) 0.80
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. Br J Cancer (2008) 0.79
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. PLoS One (2015) 0.79
Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist (2012) 0.78
A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer. Br J Cancer (2002) 0.78
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum. BMC Cancer (2007) 0.78
Role of primary surgery in advanced ovarian cancer. World J Surg Oncol (2004) 0.78
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer (2002) 0.78
Evolution of surgery in advanced epithelial ovarian cancer in a dedicated gynaecologic oncology unit-seven year audit from a tertiary care centre in a developing country. Ecancermedicalscience (2014) 0.78
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer (2006) 0.78
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer (2004) 0.78
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Br J Cancer (2005) 0.77
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol (2011) 0.77
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer (2011) 0.77
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
Report of a National Workshop on Screening for Cancer of the Cervix. CMAJ (1991) 5.37
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect Immun (1993) 4.90
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
Activity-dependent action potential invasion and calcium influx into hippocampal CA1 dendrites. Science (1995) 4.29
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med (1998) 3.98
Most classical Mus musculus domesticus laboratory mouse strains carry a Mus musculus musculus Y chromosome. Nature (1985) 3.94
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Health-related quality of life after knee replacement. J Bone Joint Surg Am (1998) 3.88
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Organ-specific restriction of transcription in mammalian chromatin. J Mol Biol (1968) 3.61
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 3.25
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science (1998) 3.22
Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 3.17
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol (2000) 3.04
The severe form of alpha thalassaemia is caused by a haemoglobin gene deletion. Nature (1974) 3.04
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol (2002) 2.99
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 2.86
Calcium action potentials restricted to distal apical dendrites of rat neocortical pyramidal neurons. J Physiol (1997) 2.77
Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol (2001) 2.77
Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet (1996) 2.76
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol (2000) 2.70
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Correlates of heavy substance use among young gay and bisexual men: The San Francisco Young Men's Health Study. Drug Alcohol Depend (2001) 2.60
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Differential HIV risk in bathhouses and public cruising areas. Am J Public Health (2001) 2.49
Multiple origins of transcription in the 4.5 Kb upstream of the epsilon-globin gene. Cell (1983) 2.47
Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 2.47
Evidence for single copies of globin genes in the mouse genome. Nature (1972) 2.45
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol (1994) 2.38
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet (1999) 2.36
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol (2001) 2.34
Space geodetic evidence for rapid strain rates in the New Madrid seismic zone of central USA. Nature (2005) 2.33
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Cytodifferentiation and embryogenesis in cell colonies and tissue cultures derived from ova and blastocysts of the rabbit. Dev Biol (1966) 2.24
Comparison of a generic (SF-36) and a disease specific (WOMAC) (Western Ontario and McMaster Universities Osteoarthritis Index) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol (1995) 2.23
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Tissue-specific transcription of the globin gene in isolated chromatin. Proc Natl Acad Sci U S A (1973) 2.15
Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer (2001) 2.12
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. Int J Gynecol Cancer (2008) 2.12
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
Corneal opacity in lumican-null mice: defects in collagen fibril structure and packing in the posterior stroma. Invest Ophthalmol Vis Sci (2000) 2.10
New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest (1993) 2.10
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
The natural history of Peyronie's disease. J Urol (1990) 2.02
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
Possible pulsed gamma ray emission above 50 MeV from the Crab pulsar. Nature (1970) 2.01
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Cigarette smoking among gay and bisexual men. Am J Public Health (1999) 1.97
Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer (2000) 1.97
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
Salmonella enteritidis phage type 4 and hens' eggs. Lancet (1988) 1.91
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Kinetic studies of gene frequency. I. Use of a DNA copy of reticulocyte 9 S RNA to estimate globin gene dosage in mouse tissues. J Mol Biol (1974) 1.87
Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol (2008) 1.86
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
Early detection of psychosis: positive effects on 5-year outcome. Psychol Med (2010) 1.82
Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer (2004) 1.80
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80